Show simple item record

dc.contributor.authorBroström, Erika
dc.contributor.authorJõgi, Rain
dc.contributor.authorGislason, Thorarinn
dc.contributor.authorBenediktsdottir, Bryndis
dc.contributor.authorBurney, Peter G J
dc.contributor.authorJanson, Christer
dc.date.accessioned2018-11-09T13:42:20Z
dc.date.available2018-11-09T13:42:20Z
dc.date.issued2018-10-01
dc.date.submitted2018-11
dc.identifier.citationThe prevalence of chronic airflow obstruction in three cities in the Nordic-Baltic region. 2018, 143:8-13 Respiratory medicineen_US
dc.identifier.issn1532-3064
dc.identifier.pmid30261997
dc.identifier.doi10.1016/j.rmed.2018.08.007
dc.identifier.urihttp://hdl.handle.net/2336/620730
dc.descriptionTo access publisher's full text version of this article click on the hyperlink belowen_US
dc.description.abstractChronic airflow obstruction (CAO) is the primary characteristic of Chronic obstructive pulmonary disease (COPD) but is also seen in chronic asthma. To compare the prevalence of CAO and possible risk factors between Tartu in Estonia, Reykjavik in Iceland and Uppsala in Sweden. All participants underwent spirometry testing of forced expiratory volume in 1 s (FEV 1037 men and 956 women participated in the study. The prevalence of CAO was lower in women in Tartu compared to the other centres (4.9% vs. 13.4 and 8.7% in Reykjavik and Uppsala, respectively, p = 0.002) while no difference was found for men. A similar picture was seen for the proportion of participants that had smoked 10 pack years or more which was much lower in Tartu for women than in Reykjavik and Uppsala, respectively (13.2% vs. 33.7 and 29.2%, p < 0.001). (Fig. 1). Of the participants with CAO the majority (57-67%) did not have a previous diagnosis of asthma or COPD.en_US
dc.description.sponsorshipALTANA Aventis AstraZeneca Boehringer-Ingelheim Chiesi GlaxoSmithKline Merck Novartis Pfizer Schering-Plough Sepracor University of Kentucky Landspitali-University Science Fund Astra Zeneca in Iceland GlaxoSmithKline in Iceland Swedish Heart-Lung Foundation Swedish Heart and Lung Association GlaxoSmithKline, Sweden Astra Zenecaen_US
dc.language.isoenen_US
dc.publisherW.B. Saundersen_US
dc.relation.urlhttps://www.sciencedirect.com/science/article/pii/S0954611118302646en_US
dc.subjectAsthmaen_US
dc.subjectCOPDen_US
dc.subjectChronic airflow obstructionen_US
dc.subjectGender differenceen_US
dc.subjectSmokingen_US
dc.subjectÖndunarfærasjúkdómaren_US
dc.subjectLangvinn lungnateppaen_US
dc.subjectLungnasjúkdómaren_US
dc.subject.meshPulmonary Disease, Chronic Obstructiveen_US
dc.titleThe prevalence of chronic airflow obstruction in three cities in the Nordic-Baltic region.en_US
dc.typeArticleen_US
dc.contributor.department1 Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Sweden. 2 Lung Clinic, Tartu University Hospital, Tartu, Estonia. 3 Department of Sleep, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Iceland. 4 Faculty of Medicine, University of Iceland, Iceland. 5 National Heart and Lung Institute, Imperial College, London, UK. 6 Department of Medical Sciences: Respiratory, Allergy and Sleep Research, Uppsala University, Sweden; National Heart and Lung Institute, Imperial College, London, UK. Electronic address: christer.janson@medsci.uu.se.en_US
dc.identifier.journalRespiratory medicineen_US
dc.rights.accessNational Consortium - Landsaðganguren_US
dc.departmentcodePAD12
dc.source.journaltitleRespiratory medicine


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record